香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 King's Stone Holdings Group Limited 金石控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1943） 截至二零二五年三月三十一日止年度 年度業績 金石控股集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈本公司 及其附屬公司（統稱「本集團」）截至二零二五年三月三十一日止年度之綜合業績連 同上一年度比較數字如下： 綜合損益及其他全面收益表 截至三月三十一日止年度 | | | 二零二五年 | 二零二四年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | | | | （經重列） | | 持續經營業務 | | | | | 收益 | 6 | 173,388 | 452,263 | | 服務成本 | | (220,525) | (434,212) | | 毛（損）╱利 | | (47,137) | ...

Core Viewpoint - Biogen has initiated a Phase 3 clinical study, PROMINENT, to evaluate the efficacy and safety of felzartamab in treating primary membranous nephropathy (PMN), a severe kidney disease with no approved treatments [1][4]. Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to develop new medicines and create value for shareholders and communities [10]. - The company has a commitment to advancing treatment options for patients with kidney diseases, as evidenced by the launch of multiple Phase 3 trials for felzartamab in 2025 [3][5]. Drug Information - Felzartamab is an investigational anti-CD38 monoclonal antibody that selectively depletes CD38+ plasma cells, which are implicated in various immune-mediated diseases [2][6]. - The drug targets patients with PMN, where up to 80% have autoantibodies against PLA2R, and aims to provide a novel treatment option in a field lacking approved therapies [2][9]. Clinical Study Details - The PROMINENT study will enroll approximately 180 adults with PMN and is expected to read out in 2029 [1]. - The trial is designed as a 104-week, randomized, open-label study comparing felzartamab to tacrolimus, with the primary endpoint being the percentage of participants achieving complete remission of proteinuria at week 104 [3][4]. - Key secondary endpoints include the impact on serum anti-PLA2R antibodies and patient-reported outcomes [3]. Previous Research - Felzartamab has shown promising results in earlier Phase 2 studies, with significant reductions in aPLA2R titers and improvements in proteinuria and serum albumin levels observed [4][6]. - The majority of treatment-emergent adverse events reported were mild to moderate, primarily infusion-related reactions [4]. Market Context - PMN is a rare immune-mediated kidney disease with an estimated prevalence of approximately 36,000 patients in the U.S., highlighting the unmet medical need in this area [6][9].

Core Insights - Chart Industries, Inc. is set to discuss its Q2 2025 financial results on July 31, 2025, at 8:30 a.m. ET, with earnings release prior to market open on the same day [1] - The company provides a live Q&A session for participants, with specific dial-in information provided [2] Company Overview - Chart Industries is a global leader in designing, engineering, and manufacturing process technologies and equipment for gas and liquid molecule handling, focusing on clean power, clean water, clean food, and clean industrials [3] - The company has a diverse product portfolio used throughout the liquid gas supply chain, including engineering, service, repair, installation, preventive maintenance, and digital monitoring [3] - Chart is a prominent provider of technology and services related to liquefied natural gas, hydrogen, biogas, and CO2 capture, among other applications [3] - The company operates 64 global manufacturing locations and over 50 service centers across various regions, ensuring accountability and transparency [3]

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UKAntev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent PaymentsJune 30, 2025 7:30 AM EDT | Source: Medicus Pharma Ltd.Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced today that they have entered into a definitive agreement da ...

BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio’s European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45xIn the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-C ...

LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced additional government funding support for its innovative AI-powered compliance solutions. Diginex’s AI-powered compliance solutions will continue to focus on helping companies comply with sustainability disclosure requirements set by the International Sustainability Standards Board (ISSB) and International Financial Reporting Standards ...

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as pa ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial services platform, announces its membership of the broad-market Russell 3000® Index and inclusion in the small-cap Russell 2000® Index, effective after US market open today, as part of the 2025 Russell indexes reconstitution. Ian Lowitt, CEO of Marex commented: “Joining the Russell US Indexes is an important milestone in our evolution as a public company. This membership will e ...

WEST PALM BEACH, FLORIDA, June 30, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has been approved to receive Scott County Opioid Abatement Funds for a second year, starting July 1, 2025 to provide care for uninsured patients from Scott County, at its Oneida, Tennessee location. Robert Merritt, Chief of Executive Officer of Myrtle stated, “We appreciate the support from Sco ...

齐鲁晚报.齐鲁壹点连宁燕 "多源"：是指新增一批小型水源工程，充分挖掘现有调蓄工程的供水潜力，实施青龙河、昌阳河等一批 河道拦蓄工程，充分利用雨洪资源，强化多水源联合调度，强化水资源战略储备，保障河湖生态流量， 改善区域农业灌溉和生产用水条件，夯实供水保障基础。 "一点"：是指威海市长会口水库工程，是市级水网规划南翼线路的核心节点工程，可兼做南水北调东线 二期(胶东输水干线工程)调蓄水库，对强化全市水安全保障具有重要战略意义。 "两线"：一是构建北翼水系连通线。依托已建的南水北调东线一期工程，连接威海市北部水源型水库， 统筹已建的泊于水库→所前泊水库连通工程，实现各水库联合调度。二是构建南翼水系连通线。依托正 在论证的南水北调东线二期工程，在已建的黄垒河地下水库→母猪河地下水库→米山水库连通工程的基 础上，向东西两侧延伸，将市域南侧水源型水库串点成线。 威海市拥有大中型水库16座、小型水库337座(其中小(1)型65座、小(2)型272座)、塘坝3014座，以及大小 河流1000多条(其中设立河长制的504条)。6月30日上午，在威海市政府新闻办的举行新闻发布会上，威 海市水务局党组成员、副局长曹永刚介绍，当 ...